Momentum Indicators for Drug Manufacturers - Major Equities -- Sanofi, TherapeuticsMD, Immune Pharma, and Heron Therapeutics

Thursday, June 30, 2016 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 30, 2016 /PRNewswire/ --

On Wednesday, June 29, 2016, the NASDAQ Composite

ended the trading session at 4,779.25, up 1.86%; the Dow Jones Industrial Average advanced 1.64%, to finish at 17,694.68; and the S&P 500 closed at 2,070.77, up 1.70%. The gains were broad based as all the sectors ended the session in positive.
has initiated coverage on the following equities: Sanofi (NYSE: SNY), TherapeuticsMD Inc. (NYSE MKT: TXMD), Immune Pharmaceuticals Inc. (NASDAQ: IMNP), and Heron Therapeutics Inc. (NASDAQ: HRTX). Learn more about these stocks by accessing their free trade alerts at:

Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The stock gained 1.75% to close the day at $41.26. The stock recorded a trading volume of 3.41 million shares, which was above its three months average volume of 2.21 million shares. The Company's shares have advanced 0.15% in the last one month and 7.06% in the past three months. The stock is trading 2.63% above its 50-day moving average. Additionally, Sanofi's stock traded at a PE ratio of 21.98 and has a Relative Strength Index (RSI) of 57.63. Sign up and read the free notes on SNY at:

On Wednesday, shares in Boca Raton, Florida headquartered women's health care product Company, TherapeuticsMD Inc., ended the session 1.16% higher at $8.71 with a total volume of 972,133 shares traded. The Company's shares have gained 36.09% in the previous three months and 10.81% in the past one year. The stock is trading 3.92% above its 50-day moving average and 17.08% above its 200-day moving average. Moreover, shares of TherapeuticsMD have an RSI of 52.28. The complimentary notes on TXMD can be downloaded in PDF format at:

New York headquartered clinical stage biopharmaceutical Company, Immune Pharmaceuticals Inc.'s stock finished Wednesday's session 6.17% higher at $0.43 with a total volume of 1.27 million shares traded. The Company's shares have gained 28.79% in the last one month. The stock is trading above its 50-day moving average by 13.96%. Immune Pharmaceuticals' stock has an RSI of 51.16. Register for free on and access the latest research on IMNP at:

On Wednesday, shares in Redwood City, California headquartered biotechnology Company, Heron Therapeutics Inc., ended the day 0.95% higher at $18.00 with a total volume of 387,243 shares traded. The stock is trading below its 50-day moving average by 7.08%. Furthermore, shares of Heron Therapeutics have an RSI of 42.49. The Company was formerly known as A.P. Pharma Inc. and changed its name to Heron Therapeutics Inc. in January 2014. Get free access to your trade alert on HRTX at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store